Christophe De Block, Belgium

Antwerp university hospital Endocrinology-Diabetology
Christophe De Block is the Head of the Department of Endocrinology, Diabetology and Metabolism and Professor at the University of Antwerp and former President of the Diabetes Liga Belgium. Prof. De Block’s main clinical and research interests are related to prediction and prevention of type 1 diabetes, autoimmune polyendocrine syndromes and new treatment options for diabetes. His latest field of interest focuses on the application of continuous glucose monitoring, functional insulin therapy and sensor-augmented pump therapy. Professor De Block has received several scientific awards, including the Award of the Royal Academy of Medicine of Belgium for experimental investigations on autoimmune diseases, the Young Investigator’s Award of the Diabetes and Nutrition Study Group 2003, the Young Investigator’s Award of the Belgian Endocrine Society in 2005 and the Novo Nordisk Award for Diabetes 2015-2016. He has published more than 120 papers in international medical journals and is a member of the Editorial Board of Current Diabetes Reviews. Prof. De Block is a member of the European Association for the Study of Diabetes (EASD), the American Diabetes Association (ADA), the Endocrine Society, the Belgian Diabetes Registry and the Belgian Endocrine Society.

Presenter of 4 Presentations

PARALLEL SESSION

NAFLD/NASH in type 1 diabetes: overrated or underappreciated

Abstract

Abstract Body

NAFLD is the most common chronic liver disease in western countries, affecting 25-30% of the general population and up to 65% in those with obesity and/or type 2 diabetes. Accumulation of visceral fat and insulin resistance (IR) are pivotal factors contributing to NAFLD. NAFLD is not an innocent entity as it not only may cause liver-associated disease but also contributes to cardiovascular morbidity and mortality.

More and more people with type 1 diabetes (T1D) are becoming overweight and present with features of IR, but the prevalence and impact of NAFLD in this population is still unclear. The utility of non-invasive risk scores to screen for NAFLD in T1D is being explored. Based upon ultrasonographic criteria NAFLD is present in ~22% in adults with T1D. MRI based data show a prevalence rate of ~8.6%. However multiple factors affect these data, ranging from study design and referral bias to discrepancies in diagnostic accuracy.

Subjects with T1D have a 7-fold higher risk of cardiovascular disease (CVD) and CV mortality is the most prominent cause of death in T1D. IR may contribute to NAFLD and to CV complications in T1D. The independent contribution of NAFLD to CV events has to be determined in this population. Furthermore, preliminary data in T1D point towards a 2-3x higher risk for microvascular complications in those with NAFLD.

We will discuss epidemiological and diagnostic challenges of NAFLD in T1D, explore the role of IR in NAFLD and NAFLD-associated complications, and examine the contribution of NAFLD to the presence of macro- and microvascular complications.

Hide
PARALLEL SESSION

Introduction

INDUSTRY SESSION

How did we get here? Insulin’s story so far

Moderator of 1 Session

PARALLEL SESSION
Date
Fri, 04.06.2021
Session Type
PARALLEL SESSION
Session Time
17:15 - 18:15
Room
Hall D